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Abstract 
A new class of 5-arylated 5-hydroxypyrrolones was derived from mucochloric acid in 2 
synthetic steps and the chemical structure was confirmed additionally by x-ray analysis. 
Using a radiolabelled binding assay, potent CCK1 selective ligands were identified (CCK1: 
12nM) and the antagonism was confirmed by using isolated tissue preparations. A series of 
isobutyl derivatives displayed unsurmountable CCK antagonistic properties and in vitro 
excellent inhibition of proliferation was obtained in cholecystokinin related cancer cell lines 
in the nanomolar range. Finally, using xenograft studies in nude mice, two selected pyrrolone 
derivatives, X=H and X= F a fluorinated analogue ( PNB-028 ), showed a strong inhibition of 
tumour growth in a chemo-resistant colon cancer- (MAC 16) and a  human pancreatic cell 
line (MIAPACA) at 50 mg/kg by oral administration. 
 
Introduction 
Cholecystokinin (CCK) acts as a neuromodulator in the brain and as a gut hormone in 
the gastrointestinal tract. CCK-ligands, agonists as well as antagonists,
1
 have been 
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extensively investigated as potential drug molecules.
2
 Originally, cholecystokinin was 
discovered to cause contractions of the gallbladder, it was then rediscovered as 
pancreozymin, triggering the release of pancreatic enzymes and then, it was confirmed 
that both peptides are identical.
3
 
Gastin, closely related to cholecystokinin, triggers the release of gastric acid and in 
vitro in cell lines, gastric cancer is gastrin dependant.
4
 Cholecystokinin does cause 
proliferation in colon- and pancreatic cancer cell lines and therefore, CCK-antagonists 
were studied as growth factor inhibitors in certain forms of cancer.
5
 They were 
evaluated as anxiolytics,
6
 in the treatment of schizophrenia,
7
 satiety
8
 and reviewed as 
anxiolytics.
9
 These properties may be beneficial in cancer patients in addition to their 
anti-neoplastic activity. 
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Fig.1 Drug design from Asperlicin, via Devazepide, a CCK1 selective antagonist, a 
CCK2 selective antagonist, L-365,260 towards Z-360, a potent and water soluble 
CCK2 antagonist. 
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Asperlicin (Fig. 1) was the first non-peptidal CCK antagonist lead structure from 
nature and analogues thereof, were studies as CCK ligands.
10
 Simplification of the 
lead structure by Merck led to Devazepide,
11
 a potent CCK1 selective cholecystokinin 
antagonist, containing a 1,4-benzodiazepine template and an indole moiety. 
Devazepide was tested clinically in 18 patients with advanced cancer
12
 without 
escalating doses and failed to show significant effects due to its poor pharmacokinetic 
properties. 
The indolyl amide of devazepide was replaced by a urea linkage and Merck’s L-
365,260 resulted in a CCK2 selective antagonist. Further subsequent SAR optimisation 
led to Zeria’s improved Z-360,
13
 in which the N-alkyl side chain, the 5- position 
(cyclohexyl) was optimised for potency and a meta-carboxylic acid on the aryl urea 
linkage was introduced to enhance water solubility of the CCK2 antagonists (Fig. 1). 
Z-360 is a CCK2 –gastrin receptor antagonist and progressed into phase 2 trial with 
pancreatic cancer.
14
 
Lorglumide is 25 times more potent in blocking the cholecystokinin induced 
contractions of the gallbladder than proglumide, but the activity to block pancreatic 
amylase secretion is only better by factor 2,
15
 indicating a heterogeneity of the CCK1 
receptor.  
Proglumide with mM activity is too non-potent, requiring multi gramme quantities for 
potential cancer treatment.  
In our search for new CCK ligands, in which the 1,4-benzodiazepine structure
16
 was 
replaced by an achiral diphenyl pyrazolone template, novel CCK antagonists with an 
indole carboxylic acid
17
 and a phenyl urea moiety
18
 were found and optimised with 
excellent animal data on anxiety and depression.
19
 The 1,4-benzodiazepine template of 
devazepide was varied by a combinatorial solid phase synthesis
20
 and was optimised in 
terms of CCK binding affinity.
21
 
Again, having realized the poor pharmacokinetic properties of these agents, a search 
for a completely novel, smaller template
22
 with a molecular weight <350, a log p about 
3 and a polar surface area for membrane penetration of less that 100A, with no urea 
linkage was initiated (Fig. 2). 
Here, we identified within a novel chemical class, potent irreversible cholecystokinin 
antagonists, which translated in vitro and in vivo efficiency into new chemical entities 
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(NCE) for the treatment of colon and pancreatic cancer. The pyrrolone 10 entered 
preclinical development (PNB-028) and showed excellent metabolic stability, a very 
high bioavailability (98%) and a half-life of 3.5 h in rats. 
 
 
CCK2      CCK1 antagonists 
O
N
O
HN Cl
O
HO
O
Cl
Cl
5-(benzyloxy)-3-chloro-4-(isobutylamino)furan-
2(5H)-one 4-chloro-5-(4-chlorophenyl)-5-hydroxy-1-isobutyl-
1H-pyrrol-2(5H)-one  
      Lactone                                     Lactame - template 
 
Fig. 2 From 4-amino-(2H)- furanones to novel hydroxyl-pyrrolones, a conversion of 
gastrin antagonists into cholecystokinin antagonists. 
 
Results and discussion 
Chemistry 
The arylated dichloro-2(5H)-furanones (Lactone A, B, C) were synthesised from 
mucochloric acid (Scheme 1), which is available from furfural under oxidising 
conditions with hydrochloric acid. Theses arylated intermediates were chemically 
optimised by us previously and evaluated as anticancer agents.
23
  
Under mild conditions, using ether as solvent, the arylated furanones  A, B, C were 
reacted with a range of amines, required for SAR optimisation towards the CCK1 
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receptor, into the desired arylated pyrrolones 1-16 in a 1 step synthesis in high yields 
(Scheme 1). 
O
Cl Cl
O
X
N
Cl
O
X
R
X=H
X=Cl
X=F Amine, ether, 
RT, 30 min
Lactone A, B,C
Lactame 1-16
O
Cl Cl
O
X
Arene, RT,
AlCl3
HO
HO
Cl Cl
OO
Mucochloric acid
HO
solvent and reagent
 
Scheme 1 Synthesis of arylated lactams 1-16. 
 
The experimental details are described in ESI under the section “materials and 
methods” and no acyclic ketone, the ring opened form of the hydroxyl-pyrrolone, was 
observed. On a small scale purification was performed by column chromatography and 
on a multigramme scale, the isobytyl series 9-11 was purified by recrystallisation with 
methanol. 
As the gold standard of structure characterisation, the x-ray structure of pyrrolone 9 
was determined. Both stereoisomers are displayed in Fig. 3. The molecule is not 
present in a keto form and fully occurred in the 5-membered ring form, as a hydroxyl 
– pyrrolone.  
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Fig. 3 X-ray structure of 4-Chloro-5-hydroxy-1-isobutyl-5-phenyl-1,5-dihydro-pyrrol-
2-one, the lactame 9 recrystallised from methanol. 
SAR optimisation 
The initial step of evaluation was to screen for potent binding affinity and to identify a 
CCK1 selective ligand for the treatment of cholecystokinin related conditions. 
Using radiolabel iodinated cholecystokinin, inhibition of binding was determined for 
all test molecules and the IC50 are outlined in Table 1.  
N-methyl group, present in lactame 1, showed no binding affinity and an increase in 
the length of the side chain resulted in micromolar binding for the iso-propyl group, as 
seen in lactame 3 and 4. 
Ring closure on the N-substituent, from isopropyl to cyclo-propyl resulted in a loss of 
activity (lactame 5, 6) and ring enlargement from a 3- membered to a 5- membered 
ring system resulted in no significant increase of binding affinity. 
The change from a propyl into a butyl group resulted in a manifold increase of activity 
and the best substituent was found isobutyl, as shown in Figure 4 for the iso-butyl 
series 9-11. The introduction of a halogen atom resulted in an increase of binding 
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affinity, possibly due to enhanced lipophilicity and the best overall molecule is 
pyrrolone 11 with an IC50 about 8 nM.  The t-butyl analogue 12 was formed in very 
low yields, same as a pentyl analogue (not included). 
Table 1 CCK binding affinity using radioligands with cortex and pancreatic 
membranes. IC50 is presented in micromolar;  N=3. 
Pyrrolone  X= R= CCK-A 
[µM] 
CCK-B 
[µM] 
1 H Me 2.5±0.2 >10 
2 Cl Me 2.0±0.2 >10 
3 H I-Pr 0.2±0.02 0.9±0.03 
4 Cl I-Pr 0.3±0.04 3.7±0.4 
5 H Cyclopropyl 7.5±0.3 >10 
6 Cl  Cyclopropyl 4±0.3 >10 
7 H Cyclopentyl 0.36±0.3 0.84±0.4 
8 Cl Cyclopentyl 2.5±0.2 10 
9 H Isobutyl 0.020±0.01 1.2±0.3 
10 F Isobutyl 0.012±0.01 0.75±0.2 
11 Cl Isobutyl 0.008±0.01 0.4±0.2 
12 H t-butyl 0.12±0.22 0.9±0.03 
13 H Hexyl 4.5±0.3 >10 
14 Cl  Hexyl 3.6±0.3 >10 
15 H Cyclohexyl >10 >10 
16 H Ph >10 >10 
17 H Bz 0.80±0.04 0.022±0.002 
Lorglumide - - 0.17±0.01 >10 
 
The n-hexyl lactame 13, 14 clearly lost activity and the same was observed for the 
cyclohexylderivative 15. Lactames, such as pyrrolone 16, containing an aromatic ring 
directly connected to the N-position showed a micromolar activity > 10µM. Most 
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interestingly, the introduction of a N-benzyl substituent to the pyrrolone template, 
instead of an alkyl group, resulted in the mixed CCK-ligand, pyrrolone 17 (Fig. 4). 
This is a new lead structure towards CCK2 selective antagonists and a full lead 
optimisation is in high progress. 
 
N
HO
O
Cl
X
X=H, Cl, F
 
Pyrrolone 9, 10, 11 
N
HO
O
Cl
X
 
Pyrrolone 17 
Fig. 4 From a CCK1 antagonist towards a CCK2 lead structure. Overview of selected 
pyrrolones (lactames). 
Generally, within the isobutyl series the halogen atom on the 5-arylated ring enhanced 
the binding affinity. The IC50 was enhanced from 20 nM for pyrrolone 9, towards the 
10nM range for the halogenated entities. Most importantly the metabolism, such as an 
expected hydroxylation in the para-phenyl position, would be blocked, resulting in 
agents with improved pharmacokinetic properties.  
Molecular modelling studies were performed to rationalise drug receptor interactions 
of the pyrrolone 11 with the CCK1 receptor. 
The isobutyl group of the ligand interacted with a hydrophobic cave of the receptor, 
centred at Ala-14. The carbonyl group in the 2- position bond via hydrogen binding 
towards the CCK receptor with Arg-9 and the N- atom of the lactame interacted with 
Glu-17. The 5-hydroxyl group of the lactame ligand displayed interactions with of 
Asn-6, which are outlined in Fig. 5.  
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Fig. 5 Drug receptor interactions of lactame 11 with the CCK1 receptor. 
The phenyl group has no interaction with tryptophan or phenylalanine and Pi - alkyl 
interactions of the chloro-phenyl group with Leu-29 and Ile-28 explain the small 
increase in specific binding. The ligand acted as irreversible inhibitor in vitro and the 
3
rd
 extracellular loop of the CCK1 receptor with the natural ligand CCK8s binding site, 
was selected to initiate modelling. It was assumed that irreversible, possibly covalent 
interaction with this loop of the receptor may deform the site and explain the 
superiority of the antineoplastic activity of this class of agents compared with 
competitive inhibitors.  
Pharmacology 
Opiate agonists, such as morphine and CCK antagonists, such as lorglumide and 
devazepide reduced electrically induced contractions on the GPI.  From the 
radioligand binding assay the iso-butyl-pyrrolones were identified as the most potent 
ligands, and the classical isolated tissue preparation served as initial functional assay, 
confirming the antagonistic properties of these ligands.  
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Fig. 6 The inhibitory effect of 0.1, 0.5 and 1.0 µM of pyrrolone 11 on electrically 
stimulated rat duodenum tissue contractions. 
 
Using the isolated rat duodenum preparation, a stable amplitude was generated and a 
reduction of this amplitude was observed dose dependently for the isobutyl series, 
which is outlined in figure 6 for the pyrrolone 11. This assay represents a fast and 
efficient way to screen for CCK antagonists using classical isolated tissue 
preparations.  
Cholecystokinin, CCK8s, induced contractions of the guinea pig gall bladder and this 
second tissue based assay was applied to reconfirm with this standard preparation the 
antagonistic properties of the potent CCK ligands. 
CCK-8s induced contractions of the gall bladder and these contractions were reduced 
dose dependently, which is outlined for pyrrolone 11 in fig. 7. The concentration - 
response curve was calculated based on the percentage response to 10
-5
 M ACh for a 
better comparison. Increased concentrations of the antagonist, pyrrolone 11 = ClIBA 
were added to the bath cumulatively and a shift of the curve to the right was observed.  
The function of the halogen atom is to enhance binding affinity/ increase lipophilicity 
and most importantly, to block metabolism of the molecules in the para – phenyl 
position. 
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Fig. 7 Mean cumulative concentration–response curve for CCK-8s in the absence and 
presence of 0.1, 0.5 and 1.0 µM ClIBA/pyrrolone 11 determined for the isolated 
guinea pig gallbladder (Internal standard:  ACh 10 µM = 100 % contraction). 
 
It appeared that the effect of the antagonist in the gallbladder assay is insurmountable 
and an irreversible inhibitor is ideal for the development of antineoplastic agents. 
Reactive chlorine in the 4- position may be suitable for covalent drug receptor 
interactions, explaining an irreversible antagonism for the isobutyl- pyrrolone series.  
The antineoplastic properties of selected NCE and standard CCK antagonists, such as 
L-365,260 (CCK2), devazepide and lorglumide (CCK1) was subsequently investigated, 
using a range of CCK associated cancer cell lines. 
In vitro cancer cell based testing 
CCK antagonists are associated with an array of therapeutic applications, but the focus 
of our research programme was to provide a non-toxic orally available CCK 
antagonist for the treatment of cancers.  
In vitro tests - Cytotoxicity assays 
In vitro tests were originally performed using a cell count assay, as the aim was to 
inhibit proliferation and not to optimise cytotoxicity, but the results were identical in 
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the methylthiazolyltetrazolium (MTT) assay, possible due to induced apoptosis. It was 
screened for an inhibitor of viability in certain CCK related cancers cell lines using the 
MTT assay.  
MIA PACA: Miapaca is a human pancreatic carcinoma cell line and selected data are 
outlined in Table 2. Pyrrolone 9 was found 20 times better in terms of IC50 
concentrations than lorglumide. Devazepide, which gave an IC50 about 1 µM showed 
agonistic activity (unpublished results). Lorglumide, a CCK1 antagonist, was acting on 
the gallbladder CCK1 receptor and not the pancreatic CCK receptor. None of the 
known CCK antagonists, devazepide or lorglumide proved to be clinical useful, which 
is in line with our results. 
AGS: AGS is a human stomach cancer cell line and was selected to screen for anti-
cancer activity within the entire GI system including the stomach.  The stomach 
contains CCK2/gastrin receptors and pyrrolone 17 occurred some CCK2 activity. 
CCK2 is gastrin and it is no surprise that a more CCK2 antagonist, (or the combination 
CCK1/CCK2) is working best on this cell line. 
PANC: The PANC cell line is a human pancreatic cell line. Pyrrolone 9 is many times 
better than devazepide / lorglumide on this selected pancreatic cell line. Cancer 
treatment is combination therapy, even for hormone dependent cancers. For this 
pancreatic cell line the synergistic effects of MK-329 = devazepide in conjunction 
with cisplatin were reported
24
 and studies to investigate pyrrolone 10, which is now 
PNB-028 with cis - platin and 5-FU are ongoing. 
Overall, pyrrolone 9, 10, 11 were not significantly different from each other and the 
parent pyrrol 9 and the halogenate fluorinated pyrrolone 10 were tested subsequently 
in vivo in xenograft models. In vitro in cell based assays they were found of equal 
selective toxicity towards 2 human pancreatic and 2 colon cancer cell lines. The 
cytotoxicity results for CCK related cell lines are outlined in table 2 with lorglumide 
and devazepide as CCK1 standard and L-365,260 as CCK2 standard. 
 
U373MG: The anticancer activity of the agents is not limited to GI cancers. The 
cytotoxicity of the glioblastoma cell line U373MG, a brain cancer cell line, was 
determined for a small series of test compounds including for Merck’s CCK2 
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antagonist L-365,260. The CCK1 antagonist, pyrrolone 9 and L-365,260 were found of 
high nanomolar activity. The mixed CCK antagonist, pyrrolone 16 showed low 
nanomolar activity and a programme for the development of mixed CCK antagonists 
on this lead structure was initiated and the results will be communicated in a second 
publication. 
 
Table 2 Cytotoxicity assay, IC50 of selected examples against a variety of GI and brain 
cell lines. IC50 values are based on inhibition of viability in the MTT assay in various 
cell lines.  
 
IC50 
[nM] 
MIA 
PACA 
AGS PANC U373MG MAC13 MAC16 
L-365,260 >5000 675±54 >1000 541±87 >5000 >5000 
Devazepide 1200 >5000 480±32 >5000 1100 1000 
Lorglumide 425±23 289±14 316±21 >5000 421±11 861±22 
Pyrrolone 9 15±4 262±18 27±9 765±29 536±32 96±25 
Pyrrolone 10 11±4 222±16 18±6 665±28 508±35 76±20 
Pyrrolone 11 13±4 242±18 22±9 475±25 526±34 86±23 
Pyrrolone 17 230±11 53±4 674±33 23±3 >1000 >1000 
 
A mixed antagonist may work best for treating brain cancers, as mengionomas express 
CCK1 receptors and astrocytomas CCK2 receptors.
25
 A human glioma cell line, U-87 
responded to CCK2 antagonists,
26
 unknown uncharacterised primary tumour cell lines 
only to mixed CCK antagonists (Lattmann & Buchfelder unpublished).  
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The antineoplastic effect, mediated by blocking CCK receptors, which are expressed 
in parts of the GI system, correlated well in vitro cell culture and isolated tissue 
preparations.  
MAC 16: MAC 13 and MAC 16 cancers are derived from the colon of the mouse and 
MAC 16 is of particular interest, as it is resistant to alkylating agents.  
For pyrrolone 9, an IC50 about 100 nM was determined for the MAC 16 cell line and 
the fluorinated analogue 10 was slightly more potent.  Most interestingly, no other 
CCK antagonist, such as L-365,260, devazepide or lorglumide was found active for 
this cell line, which is, when transplanted into mice lethal within weeks. Therefore, it 
may be concluded, that the unsurmountable irreversible properties of the antagonists 
are key to colon cancer.  
Subsequently, this tumour was studied initially in mice to analyse, if the in vitro 
results can be translated into relevant anti-tumour activity.  
Xenograft studies in nude mice 
MAC 16 tumour xenograft study 
MAC 16 tumours developed quickly within 10 days after implantation and grew 
robustly. Once the tumours reached 100 mm
3
, (Fig. 8) the animals were divided into 
the various treatment groups and treated with vehicle or the fluorinated pyrrolone 10 
and the non-halogenated derivative 9. Though MAC 16 tumours grew robustly from 
100 mm
3
 to over 1500 mm
3
 within 2-3 weeks, the animals treated with both agents 
tumours grew slower.  Both pyrrolones inhibited the tumour growth significantly from 
the day treatment was initiated and maintained tumour inhibitory activity until 
sacrifice. At sacrifice, interestingly in some animals growths was not only inhibited, 
but tumours shrinked after reaching a maximum volume. Most interestingly, while 
MAC 16 tumours in the vehicle-treated group metastasized to lungs, tumours in drug-
treated groups did not metastasize to lungs. 
Cholecystokinin is known to mediate cancer progression and metastasis, which were 
antagonised by sufficient concentrations of devazepide.
27
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One animal in vehicle-treated group died during the course of the study, which is 
typical for MAC 16 induced cancer, showing the lethality of this selected cancer 
model (Figure 8). 
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Fig. 8 Effect of pyrrolone 9 and 10 on MAC 16 colon cancer tumour growth. 
Colon cancer is generally linked with the CCK1 receptor and only under certain 
conditions it is associated with the CCK2 receptor.
28
 Gastric cancer is correlated with 
the CCK2 receptor / gastrin receptor and in the human gastric cancer cell line HT-29, 
gastrin-17 stimulated growths and theses effects were abolished by CCK2 antagonists 
such as L-365,260. In detail Colucci tested only one 1 nM concentration of 
devazepide, which stimulated growths in the study and by our own observations. Low 
nanomolar devazepide concentrations occur in vitro a CCK agonistic effect and this 
may explain why devazepide showed no significant effect in cancer previously.
12
 
Overall for the MAC 16 cell line proliferation was blocked in vitro and in vivo by our 
pyrrolone based CCK antagonists. Here, the link CCK1 receptor and colon cancer was 
confirmed experimentally. 
MIAPACA tumour xenograft study 
MIAPACA tumours developed quickly after implantation and grew modestly, though 
not as robustly as MAC 16 tumours. Once the tumours reached 100 mm
3
, the animals 
were divided into various treatment groups and were treated with vehicle or respective 
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drugs. Though vehicle-treated MIAPACA tumours grew from 100 mm
3
 to over 750 
mm
3
 within 3 weeks, pyrrolone 9 and 10 - treated tumours grew slower. 
Both agents inhibited tumour growth significantly from the day treatment was initiated 
and maintained the growth inhibitory properties until sacrifice (Fig. 9).   
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Fig. 9 Effect of pyrrolone 9 and 10 on MIAPACA pancreatic cancer tumour growth. 
Overall, it was clearly shown, that colon and pancreatic cancers response to CCK1 
antagonists and not CCK2 antagonists.
 29
 We agree, it is unlikely that, gastrin is more 
important in pancreatic cancer than cholecystokinin. It may be wise to say, that it is 
pancreozymin, via the pancreatic cholecystokinin receptor, that promotes cancer 
(CCK1b = pancreozymin receptor and not CCK1a cholecystokinin receptor) or possibly  
the CCK-C receptor. Smith clearly stated the role of the CCK-C receptor in pancreatic 
cancer
30 
and reviewed the cholecystokinin receptor as molecular target in treating 
pancreatic cancer.
31
 If it is the CCK-C receptor, then according to recent nomenclature 
-the CCK3 receptor- would be the cancer target and molecular modelling based on the 
whole receptor, generated by homology modelling would be the starting point for 
further optimisation towards the CCK3 receptor. This would be advantageous as the 
CCK1 receptor is required for the physiological role of cholecystokinin. Blocking of 
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the contractions of the gall bladder leads to gallstones in the long term and reductions 
of bile flow will result generally in liver toxicity. 
Conclusions 
This novel arylated hydroxyl-pyrrolone template was synthesised in only 2 synthetic 
steps in high overall yields from readily available starting material.  
For the potent CCK1 ligands, a full non-competitive, possible irreversible CCK 
antagonism was confirmed classically, using isolated tissue preparations, which is 
ideal for an antineoplastic agent. For this novel template, it was found, that CCK 
antagonism translated into anti-cancer activity within the GI system and the known 
CNS activity of CCK antagonists may be of additional therapeutic benefit in treating 
cancer –associated diseases.  
The isobutyl series stopped the growths of colon- and pancreatic cancer models and a 
full pre-clinical development programme was launched for the fluorinated pyrrolone 
10. The new chemical entity PNB-028 progressed into late stage pre-clinical 
development for the treatment of human pancreatic and colon cancer. 
 
All experiments were performed in compliance with the relevant laws and institutional 
guidelines. 
The xenograft studies (RD-09/102014-4482403) in mice were performed and approved by 
the bioethics committee at the University of Tennessee Health Science Center, Cancer 
Research Building 19, Manassas, Memphis, TN 38103 and it was performed from May 2014 
- July 2014 . 
 
No human subjects were involved in this study. 
 
The study was sponsored by PNB Vesper Life Sciences. 
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